The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9260506 B1

PDF
Full Text
Expired
Date of Patent:
Feb. 16, 2016

Filed:

Apr. 06, 2012
Applicants:

Grazyna Adamus, Tigard, OR (US);

Arthur A. Vandenbark, Portland, OR (US);

Inventors:

Grazyna Adamus, Tigard, OR (US);

Arthur A. Vandenbark, Portland, OR (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/00 (2006.01); C07K 14/74 (2006.01); A61K 39/00 (2006.01); A61K 38/17 (2006.01);
U.S. Cl.
CPC ...
C07K 14/70539 (2013.01); A61K 38/1774 (2013.01); A61K 39/0008 (2013.01); C07K 2319/00 (2013.01); C07K 2319/32 (2013.01);
Abstract

Methods are provided for the treatment of a retinal disorder or optic neuritis in a subject. In some embodiments, the methods include administering a therapeutically effective amount of an MHC molecule including covalently linked first, second, and third domains; wherein the first domain is an MHC class II β1 domain and the second domain is an MHC class II α1 domain, wherein the amino terminus of the α1 domain is covalently linked to the carboxy terminus of the β1 domain; or wherein the first domain is an MHC class I α1 domain and the second domain is an MHC class I α2 domain, wherein the amino terminus of the α2 domain is covalently linked to the carboxy terminus of the α1 domain; and wherein the third domain is covalently linked to the first domain and comprises a retinal antigen or an antigen of the central or peripheral nervous system.


Find Patent Forward Citations

Adamus, Grazyna. (2016). Treatment of retinal disorders with recombinant t cell receptor ligand (rtl) (U.S. Patent No. 9260506). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/9260506

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…